共查询到19条相似文献,搜索用时 140 毫秒
1.
2.
3.
目的结合药品日常监管工作实际,探讨中药饮片的质量问题。方法分析中药饮片质量与中医药历史传承、标准缺失、经济利益、工作人员素质之间的关系。结果提出了提高中药饮片质量的对策,包括重视中药材的种植质量,不断完善中药饮片质量标准,建立科学的中药饮片价格形成机制,加强技术人才的培养,建立完善的中药饮片质量监管体系。 相似文献
4.
目的结合药品日常监管工作实际,探讨中药饮片市场中以假充真、品种混淆等质量问题。方法分析中药饮片质量与中药材种植、采收、加工炮制、原药材质量、贮藏保管条件和工作人员的素质有关。结果与结论提出了解决中药饮片质量问题的对策。 相似文献
5.
中药饮片是中医药的物质基础,中药饮片的质量好坏直接关系到医疗机构临床使用的安全性和有效性。笔者根据日常中药饮片监督检查的工作实际,剖析目前基层医疗机构中药饮片质量管理中存在的现状,并从几个方面探讨如何提高医疗机构中药饮片品质的监管对策。 相似文献
6.
7.
中药饮片在防病和治病,特别是现代流行病的预防,提高人体免疫力方面发挥着重要作用。但是,由于国家对中药饮片监管的要求改变,以及长期以来没有对中药饮片的范围进行明确界定,导致中药饮片在经营、使用和监管中存在一些问题。特别是农村卫生室和个体医疗机构的中药饮片更存在一些不容忽视的问题,本文结合北京市门头沟区的现状对这个问题作一简单分析。 相似文献
8.
中药饮片质量安全问题的成因及对策 总被引:3,自引:4,他引:3
目的:提高中药饮片品质,保障用药安全有效。方法:通过对当前中药材及饮片质量安全中存在的主要问题进行逐一分析,找出成因,提出对策。结果与结论:完善法律法规体系,加强中药材源头的监督管理,建立统一的质量标准体系,加大打假治劣的监管力度,确保中药饮片的质量安全和疗效。 相似文献
9.
中药饮片在防病和冶病、流行病的预防、提高人体免疫力方面有极大的功效,发挥着重要作用.但是,由于国家对中药饮片监管的要求不同,以及中药饮片长期以来没有明确统一的界定,导致中药饮片在经营、使用和监管中存在着一些问题. 相似文献
10.
目的由客片厚朴质量问题的联想,提出当前中药饮片管理应完善、加强的措施。方法从中药饮片的生产、加工、贮藏全过程中的各个环节进行分析。结果目前中药饮片存在生产、经营混乱,缺乏统一质量标准,监管力度不强等问题。结论认为应进一步完善、加强中药饮片管理,提高中药饮片质量,加大监管力度,制定统一的质量标准和明确中药饮片的有效期,以保证人民用药安全、有效。 相似文献
11.
Traditional Chinese medicines (TCMs) have a long history for safely treating human diseases. Unlike western medicine, TCMs usually contain multiple components synergistically and holistically acting on the diseases. It remains a big challenge to represent rationally the in vivo process of multiple components of TCMs for understanding the relationship between administration and therapeutic effects. For years, efforts were always made to face the challenge, and the achievements were obvious. Here, we give an comprehensive overview of the recent investigation progress (from 2015 to 2017, except the part of ‘integrated pharmacokinetics of TCMs’ from 2014 to 2017 and the part of ‘reverse pharmacokinetics in drug discovery from natural medicines’ in 2014) on pharmacokinetics of TCMs, mainly referring to the following six aspects: (1) classical pharmacokinetic studies on TCMs; (2) absorbed components and metabolites identification of TCMs; (3) pharmacokinetic herb–drug interactions and herb–herb interactions with TCMs; (4) integrated pharmacokinetics of TCMs; (5) pharmacokinetic and pharmacodynamic combination studies to dissect the action mechanisms of TCMs; and (6) reverse pharmacokinetics in drug discovery from natural medicines. Finally, based on the insights from the recent progress and our latest efforts, we propose new perspectives on the integrated pharmacokinetics of TCMs. 相似文献
12.
The reasons for missing medications in a centralized unit dose system were studied, and means of improving the situation were recommended. Reasons for missing medications included: insufficient or incorrect medications dispensed by the pharmacy, differences in interpretations of orders by pharmacists and nurses, administration of extra medication or incorrect doses, waste of medication, administration of medication to patients other than for whom it was dispensed, delivery to wrong nursing unit, pilferage, and requests by nurses for medication before the orders were received by the pharmacy. A procedure for checking medications in unit dose carts by pharmacy and nursing personnel was implemented. Before this procedure, the rate of missing medications was 0.93% of the doses dispensed; after the procedure, the rate was 0.33%. Other recommendations designed to prevent missing medications in this unit dose system are presented. 相似文献
13.
14.
15.
多组分中药化合物组释放同步性评价方法 总被引:19,自引:1,他引:19
中药剂型中所含各组分的理化性质不同, 其释放特征往往存在差异。目前尚无定量评价此种差异的方法。基于Kalman滤波法原理, 定义了化合物组异步性特征参数“化合物组相对误差(relative chemomic error, ε)”, 并据此建立同步性参数“同步性因子(synchronization factor, SF)”和反映化合物组释放同步性的参数“平均同步因子(average synchronization factor, SFav)”等评价参数。采用随机产生的模拟数据, 示例化合物组释放同步性评价的计算过程和方法学意义。结果显示, 模拟数据的化合物组相对误差与各组分释放度变异系数呈高度线性相关(r=0.996 8); 多组分中药化合物组的释放特征不同步是中药制剂的基本特征, 而化合物组释放同步性评价可能成为中药制剂质量评价的重要内容, 本文建立的量化评价化合物组同步特征的方法能直接定量地反映多组分中药释放的异步性和同步性特征。 相似文献
16.
目的:建立痔宁片、痔康片、地榆槐角丸、槐角丸和槐花散5种含槐花/米痔疮治疗中成药中黄酮类特征成分的HPLC质量控制方法。方法:供试品中黄酮类特征成分采用甲醇-水提取,经HPLC C8柱、乙酸水溶液-乙腈流动相梯度洗脱分离,UV 280nm检测,Q-TOF电喷雾负离子鉴定。结果:痔宁片等5种中成药处方中均含有槐花/米等含黄酮类成分的关键药材,并检测到相应的8个黄酮成分:芦丁、山奈酚-3-O-芸香苷、水仙苷、柚皮苷、新橙皮苷、黄芩苷、汉黄芩苷和黄芩素。以芦丁、柚皮苷、新橙皮苷、黄芩苷4个成分作为指标成分。经方法学验证,各组分均分离良好,均在系列浓度范围内线性关系良好(r2>0.999),平均回收率在93%~99%,RSD在0.6%~4.4%。适用于痔宁片等含槐米/花中成药特征成分的含量测定。结论:该方法专属、准确,适用于含槐米/花痔疮治疗中成药中黄酮类特征成分的质量控制要求。 相似文献
17.
18.
19.
AIM: To estimate the percentage of patients dispensed alendronate who were also dispensed another drug for treatment of an upper gastrointestinal disorder ('GI' drug). METHODS: The Australian Health Insurance Commission (HIC) Pharmaceutical Benefits Scheme (PBS) database was searched to identify a cohort of patients for whom alendronate or calcitriol had been dispensed and had also been dispensed a GI drug. RESULTS: The number of patients dispensed a GI drug were 6.7% for alendronate and 7.5% for calcitriol with H(2)-receptor antagonists accounting for the majority of usage. This difference of - 0.8% (95% confidence interval -1.6, 0.1) is not significant. CONCLUSION: There was no excess use of GI drugs in patients taking alendronate compared with those taking calcitriol and the Australian HIC PBS database is useful for identifying large numbers of patients who have been dispensed combinations of drugs. 相似文献